Results 91 to 100 of about 186,683 (292)

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes? [PDF]

, 2017
Precision medicine and personalized medicine are based on the development of biomarkers, and liquid biopsy has been reported to be able to detect biomarkers that carry information on tumor development and progression.
Wei Zhang, Wenjie Xia, Liu Yang, Zhengye Lv, Chao Ni, Yin Xin   +5 more
core   +3 more sources

Circulating tumor DNA in early‐stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

EMBO Molecular Medicine, 2015
The availability of blood‐based markers to predict response of a solid tumor to treatment, estimate patient prognosis and diagnose relapse well before clinical symptoms arise, is a long‐standing hope in clinical oncology.
Taija M af Hällström, Maija Puhka, Olli Kallioniemi   +2 more
doaj   +1 more source

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma

JCO Precision Oncology, 2018
Purpose To evaluate the feasibility of using circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for the management of uveal melanoma (UM). Patients and Methods Low-coverage whole-genome sequencing was used to determine somatic chromosomal copy number alterations (SCNAs) in primary UM tumors, ctDNA, and whole-genome amplified CTCs.
Beasley, Aaron, Isaacs, Timothy, Khattak, Muhammad K., Freeman, James B., Allcock, Richard, Chen, Fred K., Pereira, Michelle R., Yau, Kyle, Bentel, Jaqueline, Vermeulen, Tersia, Calapre, Leslie, Millward, Michael, Ziman, Melanie R., Gray, Elin S.   +13 more
openaire   +3 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma

Biomolecules
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth and resistance to chemotherapy. Conventional treatments remain largely ineffective, with patient survival averaging around 18 months after diagnosis ...
Bruna Pereira de Lima, Leticia Silva Ferraz, Sylvie Devalle, Helena Lobo Borges   +3 more
doaj   +1 more source

From tumor‐centric to ecosystem‐based hypotheses in brain tumor research and care

Molecular Oncology, EarlyView.
Primary brain tumors, whether in adults or children, present a major challenge because of their dramatic prognosis and the ongoing lack of efficient therapeutic approaches. In recent years, a shift has occurred from tumor‐centric concepts to a more holistic view of these tumors as dynamic ecosystems.
Julie Gavard, Flavie Bénard, Eva Billat, Margaux Le Guyon, Victoria Maltret, Laura Merlet, Chloé Astrid Walter, Tony Avril, Eric Chevet   +8 more
wiley   +1 more source

Application of circulating tumor DNA in breast cancer

The Breast Journal, 2020
Precision medicine has been well recognized since it was proposed, and the invention of liquid biopsy meets the needs of this era. Circulating tumor DNA (ctDNA), one of the most promising components of liquid biopsies, has quickly become the focus of research in recent years because of its unique advantages in clinical application. This article reviews
Yuan Zhao, Miaomiao Sheng, Ling Zheng, Dun Xiong, Kunxian Yang, Ying Luo   +5 more
openaire   +2 more sources

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Monitoring Circulating Tumor DNA in Aggressive Large B-cell Lymphoma [PDF]

Aggressive storcellede B-celle lymfomer udgør en heterogen gruppe af lymfomer, hvor diffust storcellet B-celle lymfom er den hyppigst forekommende subtype blandt voksne på verdensplan.
Vimalathas, Gayaththri
core   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source